Caris Life Sciences (CAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of ten director nominees at the annual meeting scheduled for June 4, 2026.
Proposal to ratify Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxy holders are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Ten individuals have been nominated for election to the board of directors.
Audit committee and external auditor matters
Ratification of Deloitte & Touche LLP as the external auditor for the upcoming fiscal year is up for shareholder approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Caris Life Sciences
- Virtual meeting to elect directors and ratify Deloitte as auditor, with strong governance focus.CAI
Proxy filing23 Apr 2026 - Record 2025 revenue and margin gains; 2026 outlook targets $1B+ revenue and continued growth.CAI
Q4 202511 Apr 2026 - Record revenue growth, MCED launch, and major partnerships drive transformative expansion.CAI
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - IPO targets $364.6M to fund AI-powered oncology solutions; rapid growth, but ongoing losses.CAI
Registration Filing29 Nov 2025 - IPO targets $419M+ to fund AI-powered oncology solutions amid rapid growth and ongoing losses.CAI
Registration Filing29 Nov 2025 - AI-powered precision oncology firm seeks IPO to fund growth amid ongoing losses.CAI
Registration Filing29 Nov 2025 - Q2 revenue up 81% to $181.4M, gross margin 62.7%, FY 2025 revenue guided to $675M–$685M.CAI
Q2 202523 Nov 2025 - Q3 revenue up 113% to $216.8M, net income positive, and FY25 guidance raised.CAI
Q3 202513 Nov 2025